GlassScriptPhysician profile
Sajid A Khan
NPI 1033186002
$1,633.81
in general payments reported to CMS, 2019-2025
25 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $86.69 · 2021: $22.80 · 2022: $253 · 2023: $387 · 2024: $201 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $147.38 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $134.79 | 2019-2020 | |
| Nevro Corp. | $133.94 | 2019-2023 | Senza |
| Mml US, INC. | $122.11 | 2022 | |
| Spr Therapeutics, INC | $115.68 | 2023-2025 | Sprint Pns System |
| Abbvie INC. | $109.09 | 2023-2024 | |
| Biodelivery Sciences International, INC. | $101.24 | 2019 | |
| Electromed, INC. | $99.22 | 2022 | |
| Medtronic USA, INC. | $71.86 | 2019 | |
| Sentynl Therapeutics, INC. | $69.24 | 2019 | |
| Allergan, INC. | $61.17 | 2019-2022 | |
| Abbott Laboratories | $57.30 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $50.54 | 2023 | Xtampza |
| Vertex Pharmaceuticals Incorporated | $46.65 | 2025 | |
| Lundbeck LLC | $46.65 | 2023-2024 | Vyepti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $45.08 | 2025 | Xeomin |
| Daiichi Sankyo INC. | $34.53 | 2019 | |
| Lilly USA, LLC | $34.33 | 2023-2024 | Emgality, Amyvid |
| Eisai INC. | $31.92 | 2024 | |
| Ibsa Pharma INC. | $28.13 | 2023-2024 | Tirosint, Licart, Tirosint |
| Dexcom, INC. | $22.80 | 2021 | |
| Pfizer INC. | $21.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.81 | 2020 | |
| Impel Pharmaceuticals INC. | $15.34 | 2023 | Trudhesa |
| Seagen INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajid Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.